litlas
Log inCreate account

Solange Peters

Active 2000–2026

309
Papers
67,241
Citations
111
h-index
294
i10-index

Citations

Citations per year for Solange Peters1945: 1 citations1971: 2 citations1977: 1 citations1993: 2 citations1999: 3 citations2000: 1 citations2001: 3 citations2002: 2 citations2003: 1 citations2004: 6 citations2005: 3 citations2006: 3 citations2007: 3 citations2008: 8 citations2009: 7 citations2010: 6 citations2011: 16 citations2012: 18 citations2013: 43 citations2014: 105 citations2015: 191 citations2016: 182 citations2017: 279 citations2018: 437 citations2019: 1,951 citations2020: 3,521 citations2021: 4,095 citations2022: 3,224 citations2023: 2,577 citations2024: 4,494 citations2025: 2,316 citations2026: 57 citations1946–1970: no citations, so these years are not shown1972–1976: no citations, so these years are not shown1978–1992: no citations, so these years are not shown1994–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,454 citing papers, 18.3% of this breakdownChina: 4,540 citing papers, 15.3% of this breakdownItaly: 1,994 citing papers, 6.7% of this breakdownUnited Kingdom: 1,539 citing papers, 5.2% of this breakdownFrance: 1,458 citing papers, 4.9% of this breakdownGermany: 1,369 citing papers, 4.6% of this breakdownSpain: 1,209 citing papers, 4.1% of this breakdownJapan: 1,145 citing papers, 3.9% of this breakdownNetherlands: 954 citing papers, 3.2% of this breakdownSwitzerland: 904 citing papers, 3% of this breakdownCanada: 899 citing papers, 3% of this breakdownAustralia: 726 citing papers, 2.4% of this breakdown
0%18.3%Other 25.4%

Institutions

Fields

  • Medicine78.1%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology3.9%
  • Engineering1.1%
  • Computer Science0.4%
  • Neuroscience0.4%
  • Other2.3%

Topics

  • Cancer Immunotherapy and Biomarkers13.1%
  • Lung Cancer Treatments and Mutations9.4%
  • Lung Cancer Research Studies6.2%
  • Lung Cancer Diagnosis and Treatment4.9%
  • Cancer Genomics and Diagnostics3.1%
  • Immunotherapy and Immune Responses2.5%
  • Other60.8%

Coauthors

All papers

Open in search
  1. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

    Authors: Filipe Martins, Sofiya Latifyan, Gerasimos P. Sykiotis, Faïza Lamine, Michel H. Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex‐Crosier, Thierry Küntzer, Olivier Michielin, Solange Peters, George Coukos, François Spertini, John A. Thompson, Michel Obéid - Nature Reviews Clinical Oncology 2019 cited by 2,242

  2. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

    Authors: Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam - New England Journal of Medicine 2019 cited by 2,835

  3. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: John B.A.G. Haanen, Michel Obéid, Lavinia Spain, Franck Carbonnel, Yin-Shuang Wang, Caroline Robert, Alexander R. Lyon, Wolfgang Wick, Marie Kostine, Solange Peters, Karin Jordan, James Larkin - Annals of Oncology 2022 cited by 1,154

  4. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

    Authors: Timothy A. Chan, Mark Yarchoan, Elizabeth M. Jaffee, Charles Swanton, Sergio A. Quezada, Albrecht Stenzinger, Solange Peters - Annals of Oncology 2018 cited by 2,884

  5. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Lizza Hendriks, Keith M. Kerr, Jessica Menis, Tony Mok, Ursula Nestle, Antonio Passaro, Solange Peters, David Planchard, Egbert F. Smit, Benjamin Solomon, Giulia Veronesi, Martin Reck - Annals of Oncology 2023 cited by 790

  6. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    Authors: Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières, Anne‐Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schüler, H. Léna, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang‐We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Björn Stollenwerk, David Waterhouse, Luis Paz‐Ares - The Lancet 2023 cited by 566

  7. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

    Authors: Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martínez‐Martí, Martin Faehling, Masahiro Tsuboi, Jong Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M. Keller, Murielle Mauer, Nitish Jha, Rolf A. Stahel, Benjamin Besse, Solange Peters - The Lancet Oncology 2022 cited by 744

  8. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Authors: Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok - New England Journal of Medicine 2017 cited by 2,455

  9. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Lizza Hendriks, Keith M. Kerr, Jessica Menis, Tony Mok, Ursula Nestle, Antonio Passaro, Solange Peters, David Planchard, Egbert F. Smit, Benjamin Solomon, Giulia Veronesi, Martin Reck - Annals of Oncology 2023 cited by 580

  10. A neutrophil response linked to tumor control in immunotherapy

    Authors: Jeremy Gungabeesoon, Nicolas A. Gort-Freitas, Máté Kiss, Evangelia Bolli, Marius Messemaker, Marie Siwicki, Mehdi Hicham, Ruben Bill, Peter D. Koch, Chiara Cianciaruso, Florent Duval, Christina Pfirschke, Michael Mazzola, Solange Peters, Krisztián Homicskó, Christopher Garris, Ralph Weissleder, Allon M. Klein, Mikäel J. Pittet - Cell 2023 cited by 403

  11. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

    Authors: Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz M. Kowalski, Jerónimo Rafael Rodríguez‐Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman - The Lancet 2021 cited by 1,194

  12. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: David Planchard, Sanjay Popat, Keith M. Kerr, Silvia Novello, Egbert F. Smit, Corinne Faivre‐Finn, Tony Mok, Martin Reck, Paul E. Van Schil, Matthew D. Hellmann, Solange Peters - Annals of Oncology 2018 cited by 2,299

  13. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    Authors: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 cited by 2,575

  14. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

    Authors: Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, Maximilian Diehn, Fabrice André, Sinchita Roy‐Chowdhuri, Giannis Mountzios, Ignacio I. Wistuba, Charles Swanton, Solange Peters - Cell 2024 cited by 627

  15. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk, Suresh Senan, David Waller, Johan Vansteenkiste, Carles Escriu, Solange Peters - Annals of Oncology 2017 cited by 2,335

  16. Brain metastases

    Authors: Achal S. Achrol, Robert C. Rennert, Carey K. Anders, Riccardo Soffietti, Manmeet S. Ahluwalia, Lakshmi Nayak, Solange Peters, Nils D. Arvold, Griffith R. Harsh, Patricia S. Steeg, Steven D. Chang - Nature Reviews Disease Primers 2019 cited by 1,035

  17. Overcoming therapy resistance in EGFR-mutant lung cancer

    Authors: Antonio Passaro, Pasi A. Jänne, Tony Mok, Solange Peters - Nature Cancer 2021 cited by 538

  18. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

    Authors: Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, К. К. Лактионов, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Xiaojin Shi, Lynne Poole, Solange Peters, Edward B. Garon, Tony Mok, for the POSEIDON investigators - Journal of Clinical Oncology 2022 cited by 434

  19. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

    Authors: Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodríguez‐Abreu, Mirjana Wollner, James Chih‐Hsin Yang, Julien Mazières, Francesco Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, Hye Ryun Kim, on behalf of the KEYNOTE-604 Investigators - Journal of Clinical Oncology 2020 cited by 759

  20. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: John B.A.G. Haanen, Franck Carbonnel, Caroline Robert, Keith M. Kerr, Solange Peters, James Larkin, Karin Jordan - Annals of Oncology 2017 cited by 2,354

  21. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    Authors: Anne‐Marie C. Dingemans, Martin Früh, Andrea Ardizzoni, Benjamin Besse, Corinne Faivre‐Finn, Lizza Hendriks, Sylvie Lantuéjoul, Solange Peters, Noemı́ Reguart, Charles M. Rudin, Dirk De Ruysscher, Paul Van Schil, Johan Vansteenkiste, Martin Reck - Annals of Oncology 2021 cited by 574

  22. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

    Authors: Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters - Annals of Oncology 2020 cited by 686

  23. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

    Authors: Émilie Le Rhun, Michael Weller, Dieta Brandsma, Martin J. van den Bent, Evandro de Azambuja, Roger Henriksson, Thomas Boulanger, Solange Peters, Colin Watts, Wolfgang Wick, Pieter Wesseling, Roberta Rudà, Matthias Preusser - Annals of Oncology 2017 cited by 639

  24. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Silvia Novello, Fabrice Barlési, Raffaele Califano, Tanja Čufer, Simon Ekman, Matteo Giaj Levra, Keith M. Kerr, Sanjay Popat, Martin Reck, Suresh Senan, G.V. Simo, Johan Vansteenkiste, Solange Peters - Annals of Oncology 2016 cited by 2,636